Northwest Biotherapeutics
Company announcements, filings, publications, and corporate updates from NWBio.
Open sourcePublic-company intelligence, source by source
The Enhanced email briefing on public NWBO and DCVax developments, with source links and clear labels for what is supported and what remains unverified.
Enhanced NWBO briefing - $7/month
Filings, trials, court updates, and meaningful community claims in one source-aware briefing.
Due to the high costs of API calls and AI token usage, the Free NWBO Monitor ended after the October 31, 2026 edition. New subscriptions are available through Enhanced for $7/month.
Enhanced arrives at 6:15 PM Eastern, Monday through Saturday. No Sunday edition.
Filings, trial updates, litigation, and verified context, plus clearly labeled community signals.
Create an account, verify your email, then complete secure Stripe checkout. Creating an account alone does not charge you. Cancel anytime.
Already registered? Log in to your Enhanced account.
Public archive
Enhanced publishes Monday through Saturday, with no Sunday edition. Register above to receive new editions by email.
The source surface
Primary records can confirm a development. Community and discovery sources can identify leads that still require verification.
Company announcements, filings, publications, and corporate updates from NWBio.
Open source10-K, 10-Q, 8-K, registration, ownership, and other filings for CIK 0001072379.
Open sourceStudy registrations, status changes, sponsors, interventions, and posted results.
Open sourceUK regulator guidance and public records relevant to medicines and marketing authorization.
Open sourcePublic docket metadata and available RECAP documents for NWBO-related litigation.
Open sourcePatent applications, grants, and prosecution records tied to relevant NWBO entities.
Open sourceInternational patent publication and application records for relevant entities and technologies.
Open sourceAuthorized read-only public-index discovery for NWBO and DCVax discussion; not proof of a material claim.
Open sourcePublic community discussion and market context, retained separately from verified company records.
Open sourcePublic manual review of investor discussion and resurfaced claims.
Open sourceEvidence before interpretation
Supported directly by a primary record or named counterparty.
A statement made by NWBio that may still need independent context.
An SEC filing, regulator action, docket, or other official record.
Independent reporting with identifiable sourcing and editorial accountability.
A trial, publication, conference, or scientific record with a clear NWBO connection.
Discussion worth checking, not evidence that a claim is true.
A material claim that could not be confirmed from reliable sources.
Available evidence did not support the claim as stated.
Accurate context that is resurfacing but is not a new development.
A transparent correction attached to the affected edition or claim.
This monitor organizes public information and authorized read-only community sources. It is not affiliated with Northwest Biotherapeutics and is not investment or medical advice.